CN101611320B - 通过来自胰腺酶原粒的糖蛋白2(gp2)的免疫反应检测体液中抗体的方法用于诊断炎症性肠病和慢性胰腺炎 - Google Patents

通过来自胰腺酶原粒的糖蛋白2(gp2)的免疫反应检测体液中抗体的方法用于诊断炎症性肠病和慢性胰腺炎 Download PDF

Info

Publication number
CN101611320B
CN101611320B CN2008800030495A CN200880003049A CN101611320B CN 101611320 B CN101611320 B CN 101611320B CN 2008800030495 A CN2008800030495 A CN 2008800030495A CN 200880003049 A CN200880003049 A CN 200880003049A CN 101611320 B CN101611320 B CN 101611320B
Authority
CN
China
Prior art keywords
disease
patient
peptide
present
diagnosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2008800030495A
Other languages
English (en)
Chinese (zh)
Other versions
CN101611320A (zh
Inventor
迪尔克·罗根比克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GA Generic Assays GmbH
Original Assignee
GA Generic Assays GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE200710004909 external-priority patent/DE102007004909A1/de
Priority claimed from EP07090010A external-priority patent/EP1950222A1/de
Application filed by GA Generic Assays GmbH filed Critical GA Generic Assays GmbH
Publication of CN101611320A publication Critical patent/CN101611320A/zh
Application granted granted Critical
Publication of CN101611320B publication Critical patent/CN101611320B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4733—Acute pancreatitis-associated protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30—Processes for preparing, regenerating, or reactivating
    • B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
    • B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/067—Pancreatitis or colitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Rehabilitation Therapy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
CN2008800030495A 2007-01-26 2008-01-28 通过来自胰腺酶原粒的糖蛋白2(gp2)的免疫反应检测体液中抗体的方法用于诊断炎症性肠病和慢性胰腺炎 Active CN101611320B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE200710004909 DE102007004909A1 (de) 2007-01-26 2007-01-26 Verfahren zum Nachweis von Antikörpern aus Körperflüssigkeiten durch eine Immunreaktion mit Glykoprotein 2(GP2) aus zymogenen Granula des Pankreas zur Differentialdiagnose von entzündlichen Darmerkrankungen und chronischer Pankreatitis
DE102007004909.0 2007-01-26
EP07090010.5 2007-01-26
EP07090010A EP1950222A1 (de) 2007-01-26 2007-01-26 Verfahren zum Nachweis von Antikörpern aus Körperflüssigkeiten durch eine Immunreaktion mit Glykoprotein 2 (GP2) aus zymogenen Granula des Pankreas zur Differentialdiagnose von entzündlichen Darmerkrankungen und chronischer Pankreatitis
PCT/DE2008/000183 WO2008089756A2 (de) 2007-01-26 2008-01-28 Verfahren zum nachweis von antikörpern aus körperflüssigkeiten durch eine immunreaktion mit glykoprotein 2 (gp2) aus zymogenen granula des pankreas zur differentialdiagnose von entzündlichen darmerkrankungen und chronischer pankreatitis

Publications (2)

Publication Number Publication Date
CN101611320A CN101611320A (zh) 2009-12-23
CN101611320B true CN101611320B (zh) 2013-11-06

Family

ID=39644915

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008800030495A Active CN101611320B (zh) 2007-01-26 2008-01-28 通过来自胰腺酶原粒的糖蛋白2(gp2)的免疫反应检测体液中抗体的方法用于诊断炎症性肠病和慢性胰腺炎

Country Status (13)

Country Link
US (1) US8058019B2 (enExample)
EP (1) EP2126582B1 (enExample)
JP (1) JP5603083B2 (enExample)
KR (1) KR101283710B1 (enExample)
CN (1) CN101611320B (enExample)
AT (1) ATE515704T1 (enExample)
AU (1) AU2008209176B2 (enExample)
CA (1) CA2674021C (enExample)
DK (1) DK2126582T3 (enExample)
ES (1) ES2369544T3 (enExample)
PL (1) PL2126582T3 (enExample)
PT (1) PT2126582E (enExample)
WO (1) WO2008089756A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7195759B2 (en) * 2001-06-06 2007-03-27 The University Of Manitoba Therapeutic uses of glandular kallikrein
GB0905076D0 (en) * 2009-03-24 2009-05-06 Total Scient Ltd Diagnostic kits and methods
EP2521915A4 (en) * 2010-01-04 2013-05-29 Mayo Foundation PERIPHERINE-SPECIFIC AUTOANTIKÖRPER AS A MARKER FOR NEUROLOGICAL AND ENDOCRINOLOGICAL DISEASES
US20130315891A1 (en) 2012-05-25 2013-11-28 Matthew Charles Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
US20130323222A1 (en) 2012-06-04 2013-12-05 Matthew Charles Human tissue kallikrein 1 glycosylation isoforms
EP2913675B1 (en) * 2014-02-28 2020-02-12 GA Generic Assays GmbH GP2 isoforms and their use in autoantibody capture
US11340235B2 (en) * 2014-02-28 2022-05-24 Ga Generic Assays Gmbh GP2 isoforms and their use in autoantibody capture
EP3299818B1 (en) * 2016-09-26 2019-12-04 GA Generic Assays GmbH Method for the diagnosis of acute pancreatitis (ap) by detection of glycoprotein 2 isoform alpha (gp2a)
WO2018065300A1 (en) * 2016-10-04 2018-04-12 F. Hoffmann-La Roche Ag System and method for identification of a synthetic classifier
AU2018230478B2 (en) 2017-03-09 2025-01-23 Diamedica Inc. Dosage forms of tissue kallikrein 1
EP3477300A1 (de) * 2017-10-25 2019-05-01 Euroimmun Medizinische Labordiagnostika AG Zellulose-basierter immunadsorber
WO2021062347A1 (en) * 2019-09-27 2021-04-01 Duke University Compositions and methods for the prevention and treatment of pancreatitis
CN110806485A (zh) * 2019-11-12 2020-02-18 广州医科大学附属第二医院 一种胶质纤维酸性蛋白抗体检测试剂盒及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996017873A1 (en) * 1994-12-06 1996-06-13 Alphagene, Inc. Diagnosis of pancreatitis
CN1225723A (zh) * 1996-07-18 1999-08-11 戴特莱夫·舒潘 检测针对组织转谷氨酰胺酶(tTG)的抗体的免疫方法,tTG在诊断和治疗控制中的用途,和含tTG的口服药剂
US6100098A (en) * 1997-02-18 2000-08-08 Mcgill University Anti-AGE IgG and uses thereof for the diagnosis of severe disease
WO2001094409A2 (en) * 2000-06-07 2001-12-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of pancreatic cancer
WO2006022643A1 (en) * 2004-07-26 2006-03-02 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detecting pancreatic disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004005319A (ja) 2002-04-24 2004-01-08 Japan Science & Technology Corp 遺伝子データベース作成方法、遺伝子データベース作成装置、遺伝子データベース作成プログラム、および遺伝子データベース作成プログラムを記録したコンピュータ読み取り可能な記録媒体

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996017873A1 (en) * 1994-12-06 1996-06-13 Alphagene, Inc. Diagnosis of pancreatitis
CN1225723A (zh) * 1996-07-18 1999-08-11 戴特莱夫·舒潘 检测针对组织转谷氨酰胺酶(tTG)的抗体的免疫方法,tTG在诊断和治疗控制中的用途,和含tTG的口服药剂
US6100098A (en) * 1997-02-18 2000-08-08 Mcgill University Anti-AGE IgG and uses thereof for the diagnosis of severe disease
WO2001094409A2 (en) * 2000-06-07 2001-12-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of pancreatic cancer
WO2006022643A1 (en) * 2004-07-26 2006-03-02 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detecting pancreatic disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
丁震等.GP2对慢性胰腺炎诊断价值的研究.《2005年全国慢性胰腺炎学术大会专集》.2005, *
丁震等.糖蛋白-2与胰腺炎.《临床内科杂志》.2004,第21卷(第6期), *

Also Published As

Publication number Publication date
CN101611320A (zh) 2009-12-23
AU2008209176A2 (en) 2009-09-10
US8058019B2 (en) 2011-11-15
PT2126582E (pt) 2011-10-11
EP2126582B1 (de) 2011-07-06
JP5603083B2 (ja) 2014-10-08
EP2126582A2 (de) 2009-12-02
CA2674021C (en) 2018-10-16
AU2008209176A1 (en) 2008-07-31
ES2369544T3 (es) 2011-12-01
PL2126582T3 (pl) 2011-12-30
US20100184662A1 (en) 2010-07-22
JP2010519180A (ja) 2010-06-03
KR20090107034A (ko) 2009-10-12
ATE515704T1 (de) 2011-07-15
WO2008089756A2 (de) 2008-07-31
CA2674021A1 (en) 2008-07-31
DK2126582T3 (da) 2011-10-10
WO2008089756A3 (de) 2008-10-16
AU2008209176B2 (en) 2013-01-31
KR101283710B1 (ko) 2013-07-15

Similar Documents

Publication Publication Date Title
US8058019B2 (en) Method for assaying antibodies in body fluids by immune reaction with glycoprotein 2 (GP2) from zymogenic granules of the pancreas for the differential diagnosis of inflammatory intestinal diseases and chronic pancreatitis
Kurup et al. Selected recombinant Aspergillus fumigatus allergens bind specifically to IgE in ABPA
US11549952B2 (en) Method for the diagnosis of acute pancreatitis (AP) by detection of glycoprotein 2 isoform alpha (GP2A)
Korponay–Szabó et al. Tissue transglutaminase is the target in both rodent and primate tissues for celiac disease–specific autoantibodies
JPH05264553A (ja) ヘリコバクターピロリ検出用の抗原調製物
TW202607014A (zh) 用於主動脈剝離檢測的蛋白抗原組合及應用
ES2790577T3 (es) Isoformas de GP2 y su uso en la captura de autoanticuerpos
Temmesfeld-Wollbrueck et al. Granulomatous gastritis in Wegener's disease: differentiation from Crohn's disease supported by a positive test for antineutrophil antibodies
JP5231477B2 (ja) 関節炎の診断および治療のためのグルコース−６−ホスフェートイソメラーゼおよびその抗体の使用、ならびに抗関節炎化合物の試験
Wheeler et al. Enzyme-linked immunosorbent assay for circulating anti-glomerular basement membrane antibodies
HK1136350A (en) Method for assaying antibodies in body fluids by immune reaction with glycoprotein 2 (gp2) from zymogenic granules of the pancreas for the differential diagnosis of inflammatory intestinal diseases and chronic pancreatitis
WO2019015814A1 (en) USE OF CHITINASE-3 PROTEIN-1 (CHI3L1) AS AUTO-ANTIGEN IN AUTOIMMUNE DISORDERS OF THE DIGESTIVE SYSTEM
US11340235B2 (en) GP2 isoforms and their use in autoantibody capture
JP2009014521A (ja) 睡眠時無呼吸症候群の診断方法
Kirk et al. Pepsinogen--an immunoglobulin binding artefact in'collagen'preparations
Jójárt Plasminogen activator inhibitor type 1, as a novel faecal biomarker in Inflammatory Bowel Diseases
CN121969937A (zh) 通过检测粪便中的糖蛋白2(gp2)来诊断微生物群失调的方法
RU2618402C1 (ru) Способ прогнозирования развития тромботических осложнений после панкреатодуоденальной резекции при раке головки поджелудочной железы
US20060143723A1 (en) Use of glucose-6-phosphate isomerase and antibodies thereto for the diagnosis and therapy of arthritis, and test of anti-arthritic compounds
Caturla et al. Occurrence of antibodies to protease-treated histones in a patient with vasculitis
RU2088937C1 (ru) Иммуносорбент для получения моноспецифической антисыворотки к транстиретину человека
EP1950222A1 (de) Verfahren zum Nachweis von Antikörpern aus Körperflüssigkeiten durch eine Immunreaktion mit Glykoprotein 2 (GP2) aus zymogenen Granula des Pankreas zur Differentialdiagnose von entzündlichen Darmerkrankungen und chronischer Pankreatitis
DE102007004909A1 (de) Verfahren zum Nachweis von Antikörpern aus Körperflüssigkeiten durch eine Immunreaktion mit Glykoprotein 2(GP2) aus zymogenen Granula des Pankreas zur Differentialdiagnose von entzündlichen Darmerkrankungen und chronischer Pankreatitis
WO2002014541A1 (fr) Methode d'examen d'une infection a $m(f)i$m(g)helicobacter pylori$m(f)/i$m(g) et kit de diagnostic

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1136350

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1136350

Country of ref document: HK